Advanced Diabetes Technology – Conversations and Collaborations
CME Credits:
MOC Credits:


Advanced Diabetes Technology

After registering for this course, it will be added to your list of activities in the AACE Learning Center. Visit the Learning Center for materials and join the live webinar on Aug. 24 at 1:00 PM EDT.

AACE’s Advanced Diabetes Technology – Conversations and Collaborations is designed to equip endocrine care team members with evidence-based knowledge and increased competence about how to use diabetes technology and devices to guide and modify treatment approaches for persons with diabetes.

Prepare for this live session by checking out the accompanying enduring activity — also free! We recommend completing the enduring activity prior to attending the live session as it lays the foundation for the live presentation — plus you'll get additional CME credit.

CME Credits
MOC Credits

Target Audience

This educational initiative is intended for all members of the endocrine care team.

Learning Objectives

Through this education, learners will improve their abilities to:

  • Assess  differences and appropriate settings for CGMs, connected pens, insulin pumps, and integrated devices.
  • Identify interventions which can add value to A1c interpretation and maintain “in-target” glucose values to improve patient adherence and reduce the occurrence of dysglycemia.
  • Incorporate diabetes technologies that are effective in managing your patients in special populations and individual needs as well as resources to address services not covered by insurance.

Commercial Support

This activity is supported by independent educational grants from Abbott Diabetes Care, Dexcom, Lilly, Medtronic, and Novo Nordisk.


Lucy H. Thornton, MSN, APRN, FNP-BC
Division of Endocrinology
Mayo Clinic Florida

Accreditation and Designation Statements

Accreditation and Designation


The American College of Endocrinology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


We will be seeking accreditation for 1 continuing nursing education contact hour.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Statement of Need

This initiative is designed to equip endocrine care team members with evidence-based knowledge and increased competence about how to use diabetes technology and devices to guide and modify treatment approaches for patients with diabetes.

Disclosures/Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE)requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Lucy H. Thornton, MSN, APRN, FNP-BC, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.